Acoramidis approved in EU for treatment of ATTR-CM
Acoramidis has been approved in the EU for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM).
Acoramidis has been approved in the EU for the treatment of wild-type or variant transthyretin amyloidosis in adult patients with cardiomyopathy (ATTR-CM). The approval was based on positive results from the Phase III ATTRibute-CM study. This study showed that treatment with acoramidis had a beneficial effect on the hierarchical composite of all-cause mortality, CV hospitalization, change in HF severity or change in exercise tolerance in ATTR-CM patients compared to placebo. Overall, acoramidis was safe and well tolerated.
Transthyretin amyloid cardiomyopathy (ATTR-CM) is a progressive disease. It is characterized by the deposition of TTR amyloid, consisting of misfolded TTR aggregates, in the heart. Acoramidis has demonstrated near-complete (≥90%) stabilization of TTR, thereby minimizing amyloid formation.
Acoramidis will be launched in Europe in the first half of this year.